Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

49.71USD
28 Apr 2017
Change (% chg)

$-1.20 (-2.36%)
Prev Close
$50.91
Open
$50.85
Day's High
$51.33
Day's Low
$49.60
Volume
762,564
Avg. Vol
684,024
52-wk High
$67.74
52-wk Low
$35.84

AGIO.O

Chart for AGIO.O

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $2,349.84
Shares Outstanding(Mil.): 47.27
Dividend: --
Yield (%): --

Financials

  AGIO.O Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -5.06 -- --
ROI: -44.21 -0.42 13.25
ROE: -56.41 5.87 14.41

BRIEF-Agios announces closing of over-allotment option in public offering

* Agios announces closing of over-allotment option in public offering

Apr 28 2017

BRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target

* Agios and aurigene enter into exclusive license agreement for novel small molecules for cancer metabolism target

Apr 27 2017

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Mar 13 2017

BRIEF-Agios says cash, marketable securities were $573.6 mln as of Dec. 31

* Agios reports fourth quarter and full year 2016 financial results and highlights key 2017 milestones

Feb 16 2017

BRIEF-Agios pharmaceuticals AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

* AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

Jan 09 2017

BRIEF-Agios provides early-stage data on AG-120 in glioma, chondrosarcoma patients

* Agios announces phase 1 data from dose expansion cohorts of AG-120 in patients with IDH1 mutant positive glioma and chondrosarcoma Source text for Eikon: Further company coverage:

Nov 18 2016

BRIEF-Agios posts Q3 shr loss $1.63

* Agios Pharmaceuticals inc - now expects to end 2016 with more than $550 million of cash, cash equivalents and marketable securities

Nov 03 2016

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $33.92 +0.06
Novartis AG (NOVN.S) CHF76.55 -0.35
Roche Holding Ltd. (ROG.S) CHF260.30 0.00
Roche Holding Ltd. (RO.S) CHF260.50 -1.00
Sanofi SA (SASY.PA) €86.61 +0.64
AstraZeneca plc (AZN.L) 4,637.50 -60.50
GlaxoSmithKline plc (GSK.L) 1,550.00 -8.50
Eli Lilly and Co (LLY.N) $82.06 +0.73
Shire PLC (SHP.L) 4,537.00 -65.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates